Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
- 28-week data from the Phase 2b VANTAGE PBC study highlights statistically significant improvements in pruritus and numeric improvements in fatigue, the two most burdensome symptoms of PBC - Seventy ...
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the ...
Please provide your email address to receive an email when new articles are posted on . Results presented at The Liver Meeting demonstrated volixibat (Mirum Pharmaceuticals) significantly improved ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...
Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results